Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MEL109112011, MEL109112011R4 | Other Grant/Funding Number | Fundacion de investigacion san Ramon (FISAR) | |
| MEL109112011R5, MEL131032017R1 | Other Grant/Funding Number | Fundacion de investigacion san Ramon (FISAR) | |
| MEL205062018, REH042024-01 | Other Grant/Funding Number | Fundacion de investigacion san Ramon (FISAR) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
EARLY-PREG is an open-cohort clinical study with a preconception, longitudinal, bidirectional and counterfactual design. The aim of this cohort is to investigate the proteomic signatures of maternal-embryonic communication by interrogating a growing biorepository of maternal fluids and tissues collected during the first two weeks after fertilisation.
Participants in the EARLY-PREG cohort consist of healthy couples seeking pregnancy, as well as women who are not seeking to conceive. The three main outcomes in the cohort are defined according to menstrual cycles in which conception is achieved and those in which conception is not achieved. Their clinical definitions are as follows:
Successful pregnancy depends on a coordinated exchange of signals between the early embryo and the mother. This complex process begins immediately after fertilisation, during the pre-implantation period. Although it plays a critical role in preparing the maternal environment for pregnancy, the mechanisms behind this communication remain incompletely understood.
The unique 'dialogue' between the embryo and the mother is a bidirectional exchange known as embryo-maternal crosstalk. Evidence indicates that this interaction, mediated by molecular signals present in uterine fluid, supports appropriate embryo implantation and modulates the maternal immune system to facilitate tolerance of the developing embryo.
To date, the majority of knowledge in this field has been derived from animal models and in vitro studies, which may not fully represent the physiology of spontaneous human conception. The EARLY-PREG preconception open cohort has been established to address this gap by characterising embryo-maternal crosstalk in vivo. This study follows healthy women who are trying to become pregnant, following them from before conception through the first two weeks of a natural conception, with continued follow-up into pregnancy and childbirth.
Daily collection of a range of biological samples - including saliva, urine, blood, cervicovaginal fluid and cervicovaginal brushings - is undertaken during key phases of the menstrual cycle. These samples are processed, preserved and stored in a dedicated biorepository for subsequent analysis using omics-based approaches.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CONCEPTION CYCLE | Conception cycle refers to the menstrual cycle in which the ovum is fertilised, leading to pregnancy. Confirmation of a conception cycle requires beta-hCG levels above the clinical threshold for a positive pregnancy test, which is determined in peripheral venous blood on the 14th day post-ovulation. |
| |
| NON-CONCEPTION CYCLE | Non-conception cycle refers to a menstrual cycle in which pregnancy does not occur. When referring to the same individual, it is, by definition, considered the counterfactual to the conception cycle described above. Confirmation of a non-conception cycle requires a clinically negative beta-hCG test, determined in peripheral venous blood on the 14th day post-ovulation. This cycle is characterised by the absence of a clinical pregnancy. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| EMBRYO EXPOSURE | Other | The counterfactual design of EARLY-PREG enables the comparison of the systemic and localised physiological effects associated with embryo appearance and implantation in an individual (the factual) against the physiological state of the same individual without experiencing pregnancy (the counterfactual). |
| Measure | Description | Time Frame |
|---|---|---|
| Number of menstrual cycles leading to full-term pregnancies | This outcome refers to the menstrual cycle in which the ovum is fertilised, leading to pregnancy with a full term live birth. The conception cycle requires beta-hCG levels above the clinical threshold for a positive pregnancy test, which is determined in peripheral venous blood on the 14th day post-ovulation. | From enrollment for up to six menstrual cycles (each cycle ranges from 21-35 days) or until pregnancy resulting in live birth, whichever occurs first. |
| Number of menstrual cycles not leading to pregnancy | This outcome refers to a menstrual cycle in which pregnancy does not occur. When referring to the same individual, it is, by definition, considered the counterfactual to the conception cycle described above. A non-conception cycle is confirmed by a clinically negative beta-hCG test, which is determined in peripheral venous blood on the 14th day post-ovulation. This cycle is characterised by the absence of a clinical pregnancy. | From enrollment for up to six menstrual cycles (each cycle ranges from 21-35 days) or until pregnancy occurs, whichever occurs first. |
| Number of menstrual cycles leading to early pregnancy loss | This outcome refers to the menstrual cycle in which the ovum is fertilised, leading to a miscarriage until 12 6/7 weeks. The conception cycle requires beta-hCG levels above the clinical threshold for a positive pregnancy test, which is determined in peripheral venous blood on the 14th day post-ovulation. | From the time beta-hCG levels rise above the clinical threshold for a positive pregnancy test until a miscarriage occurring up to 12 6/7 weeks. |
Not provided
Not provided
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Women visiting gynaecologists, and midwives in private practices, public hospitals, and Family Health Centres (CESFAMs) in the Biobio region of Chile.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Elard S Koch | Contact | +56 41 246 7242 | ekoch@melisainstitute.org | |
| Patricio A Alcaino | Contact | +56 41 246 7242 | palcaino@melisainstitute.org |
| Name | Affiliation | Role |
|---|---|---|
| Elard S Koch | MELISA Institute Genomics & Proteomics Research SpA | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ClÃnica Sanatorio Alemán | Recruiting | Chiguayante | Chile |
Not provided
| Label | URL |
|---|---|
| MELISA Institute | View source |
Not provided
All IPD information underlying the results of a publication will be shared with the sole exception of sensitive information that could reveal a person's identity.
January 2027 - December 2028
The protocol data and results will be deposited in appropriate public repositories.
Not provided
Not provided
Not provided
Not provided
Not provided
Saliva, urine, blood, cervicovaginal fluid, cervical brushings, umbilical cord blood and placenta.
|
| ID | Term |
|---|---|
| D000022 | Abortion, Spontaneous |
| ID | Term |
|---|---|
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided